FY2024 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Decreased by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Stock analysts at William Blair lowered their FY2024 EPS estimates for shares of Sarepta Therapeutics in a report issued on Wednesday, April 17th. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings per share of $6.66 for the year, down from their prior estimate of $6.74. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.14 per share. William Blair also issued estimates for Sarepta Therapeutics’ FY2025 earnings at $14.91 EPS.

A number of other equities analysts have also commented on SRPT. Barclays raised their price target on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Royal Bank of Canada raised their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Evercore ISI raised their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a research report on Tuesday, February 20th. BMO Capital Markets initiated coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 price target on the stock. Finally, Mizuho raised their target price on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $158.38.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $116.55 on Friday. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. The firm’s 50-day simple moving average is $126.75 and its 200 day simple moving average is $110.43. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business had revenue of $396.80 million for the quarter, compared to analyst estimates of $387.18 million. During the same period last year, the firm earned ($1.24) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 53.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $28,000. Montag A & Associates Inc. acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $30,000. Cary Street Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares during the period. KB Financial Partners LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter valued at $36,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,815,030. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.